in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
88 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog<br />
❚ growth factors<br />
VEGF - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0672<br />
[Custom offer]<br />
Please contact us at:<br />
customresearch@cerep.com<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
HUV-EC-C cells<br />
[ 125 I]VEGF (0.015 nM)<br />
0.03 nM<br />
VEGF (3 nM)<br />
VEGF (IC 50 : 0.016 nM)<br />
Gitay-Goren, H. et al. (1996) J. Biol. Chem., 271: 5519-5523.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
β<br />
<br />
<br />
❚ Imidazol<strong>in</strong>e<br />
I 1 - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0642<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Diversity profile<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
bov<strong>in</strong>e adrenal medulla glands<br />
Ligand [ 3 H]clonid<strong>in</strong>e (15 nM) (+ 10 µM RX 821002)<br />
Kd<br />
16 nM<br />
Non specific rilmenid<strong>in</strong>e (10 µM)<br />
Reference<br />
rilmenid<strong>in</strong>e (IC 50 : 230 nM)<br />
Molder<strong>in</strong>g, G.J. et al. (1993) Naun.-Sch. Arch. Pharm., 348: 70-76.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-10 -9 -8 -7 -6 -5<br />
log [drug] (M)<br />
rilmenid<strong>in</strong>e<br />
I 2 - antagonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0081<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Diversity profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
rat cerebral cortex<br />
[ 3 H]idazoxan (2 nM) (+ 1 µM yohimb<strong>in</strong>e)<br />
4 nM<br />
cirazol<strong>in</strong>e (10 µM)<br />
idazoxan (IC 50 : 8.4 nM)<br />
Brown, C.M. et al. (1990) Brit. J. Pharmacol., 99: 803-809.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-11 -10 -9 -8 -7 -6 -5 -4<br />
log [drug] (M)<br />
idaxoxan<br />
guanabenz<br />
clonid<strong>in</strong>e<br />
phentolam<strong>in</strong>e<br />
❚ Insul<strong>in</strong><br />
<strong>in</strong>sul<strong>in</strong> - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 0084<br />
[Custom offer]<br />
Please contact us at:<br />
customresearch@cerep.com<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
rat liver<br />
[ 125 I]<strong>in</strong>sul<strong>in</strong> (0.03 nM)<br />
8 nM<br />
<strong>in</strong>sul<strong>in</strong> (10 µM)<br />
<strong>in</strong>sul<strong>in</strong> (IC 50 : 17 nM)<br />
Koch, R. and Weber, U. (1981) Hoppe-Seyler’s Z. Physiol. Chem., 362: 347-351.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-10 -9 -8 -7 -6<br />
log [drug] (M)<br />
<strong>in</strong>sul<strong>in</strong><br />
glucagon